Infante, Jeffrey R
Korn, Ronald L
Rosen, Lee S
LoRusso, Patricia
Dychter, Samuel S
Zhu, Joy
Maneval, Daniel C
Jiang, Ping
Shepard, H Michael
Frost, Gregory
Von Hoff, Daniel D
Borad, Mitesh J
Ramanathan, Ramesh K
Article History
Received: 11 April 2017
Revised: 10 July 2017
Accepted: 25 August 2017
First Online: 26 September 2017
Change Date: 23 January 2018
Change Type: Correction
Change Details: This article has been corrected since Advance Online Publication and a corrigendum is also printed in this issue
Competing interests
: JRI reports that his institution has received research funding from Halozyme Therapeutics, Inc. RLK reports being a shareholder of Imaging Endpoints Core Lab. DDVH reports receiving a research grant to his institution from Halozyme Therapeutics, Inc. and is a consultant for Imaging Endpoints. LSR reports receiving a research grant to his institution from Halozyme Therapeutics, Inc. for the conduct of these clinical trials. PLR is currently on the DSMC for the pivotal phase 3 clinical trial of PEGPH20 in pancreatic cancer, sponsored by Halozyme Therapeutics, Inc., SSD is a shareholder of stock at Halozyme Therapeutics, Inc. and full-time employee at Fate Therapeutics. SSD, JZ, and GF were employees of Halozyme Therapeutics, Inc. at the time this trial was conducted. GF is a shareholder of stock at Halozyme Therapeutics, Inc. DCM, PJ, and HMS were employees of Halozyme Therapeutics, Inc. at the time this manuscript was submitted. RKR reports receiving research funding from Merrimack Pharmaceuticals. The other authors declare no conflict of interest.